Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Toripalimab for Bladder Preservation in MIBC
NCT07151560Phase 2Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in muscle-invasive bladder cancer (MIBC), sponsored by Renmin Hospital of Wuhan University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07151560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151560.